Veeco Announces Private Exchanges and Cancellation of Remaining 3.75% Convertible Notes due 2027
May 15, 2025 17:00 ET | Source: Veeco Instruments Inc. PLAINVIEW, N.Y.,…
NORTH AMERICAN MANUFACTURERS REPORT SHARP PULLBACK DUE TO TARIFFS, WHILE ASIAN SUPPLIERS RUN AT FULL TILT: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
In March, global supply chains spare capacity increased to highest level since…
MSMEs Cannot Afford Additional INR 1.5 Lakhs per year as Cost of Compliance due to IMS: India SME Forum
NEW DELHI, April 1, 2025 /PRNewswire/ -- The India SME Forum (ISF), the…
NYSE Content advisory: Pre-Market Update + Federal Reserve Decision Due
NEW YORK, March 19, 2025 /PRNewswire/ -- The New York Stock Exchange…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
November 11, 2024 18:00 ET | Source: MediciNova, Inc. LA JOLLA, Calif.,…